A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children

Cheikh Sokhna, Badara Cissé, El Hadj Bâ, Paul Milligan, Rachel Hallett, Colin Sutherland, Oumar Gaye, Denis Boulanger, Kirsten Simondon, François Simondon, Geoffrey Targett, Jo Lines, Brian Greenwood, Jean-François Trape, Cheikh Sokhna, Badara Cissé, El Hadj Bâ, Paul Milligan, Rachel Hallett, Colin Sutherland, Oumar Gaye, Denis Boulanger, Kirsten Simondon, François Simondon, Geoffrey Targett, Jo Lines, Brian Greenwood, Jean-François Trape

Abstract

In the Sahel, most malaria deaths occur among children 1-4 years old during a short transmission season. A trial of seasonal intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) and a single dose of artesunate (AS) showed an 86% reduction in the incidence of malaria in Senegal but this may not be the optimum regimen. We compared this regimen with three alternatives.

Methods: 2102 children aged 6-59 months received either one dose of SP plus one dose of AS (SP+1AS) (the previous regimen), one dose of SP plus 3 daily doses of AS (SP+3AS), one dose of SP plus three daily doses of amodiaquine (AQ) (SP+3AQ) or 3 daily doses of AQ and AS (3AQ+3AS). Treatments were given once a month on three occasions during the malaria transmission season. The primary end point was incidence of clinical malaria. Secondary end-points were incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to SP.

Findings: The incidence of malaria, and the prevalence of parasitaemia at the end of the transmission season, were lowest in the group that received SP+3AQ: 10% of children in the group that received SP+1AS had malaria, compared to 9% in the SP+3AS group (hazard ratio HR 0.90, 95%CI 0.60, 1.36); 11% in the 3AQ+3AS group, HR 1.1 (0.76-1.7); and 5% in the SP+3AQ group, HR 0.50 (0.30-0.81). Mutations associated with resistance to SP were present in almost all parasites detected at the end of the transmission season, but the prevalence of Plasmodium falciparum was very low in the SP+3AQ group.

Conclusions: Monthly treatment with SP+3AQ is a highly effective regimen for seasonal IPT. Choice of this regimen would minimise the spread of drug resistance and allow artemisinins to be reserved for the treatment of acute clinical malaria.

Trial registration: ClinicalTrials.gov NCT00132548.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.
Figure 2. Kaplan Meier estimate of the…
Figure 2. Kaplan Meier estimate of the cumulative incidence of malaria during the 3 months of follow-up.

References

    1. Bremen J. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 2001;(64 supplement):1–11.
    1. Lengeler C. The Cochrane Library, Issue 4. Oxford: Update Software; 2001. Insecticide-treated bednets and curtains for preventing malaria (Cochrane Review).
    1. Geerligs PDP, Brabin BJ, Eggelete TA. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ. 2003;81:205–216.
    1. Greenwood BM. The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg. 2004;70:1–7.
    1. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo- controlled trial. Lancet. 2001;357:1471–77.
    1. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, et al. Intermittent preventive antimalarial treatment for Tanzanian infants; follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet. 2005;365:1481–83.
    1. Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, et al. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet. 2003;361:1853–60.
    1. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005;331:727–33.
    1. Macete E, Aide P, Espasa M. Efficacy and safety of intermittent preventive treatment administered through the EPI scheme on the prevention of malaria in Mozambican infants. Acta Tropica. 2005;(95 supplement):S5.
    1. Intermittent Preventive Treatment in Malaria Consortium. .
    1. Etard JF, Le Hesran JY, Diallo A, Diallo J-P, Ndiaye JL, et al. Childhood mortality and probable causes of death using verbal autopsy in Niakhar, Senegal, 1989–2000. Int J Epidemiol. 2004;33:1286–1292.
    1. Jaffar S, Leach A, Greenwood AM, Jepson A, Muller O. Changes in the pattern of infant and childhood mortality in Upper River Division, The Gambia from 1989–1993. Trop Med Int Hlth. 1997;2:28–37.
    1. Dicko A, Sagara S, Sissoko MS, Guindo O, Diallo ABI, et al. Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children aged 6 months to 10 years in Kambila, Mali. Amer J Trop Med Hyg. 2004;(71 supplement):S6.
    1. Cisse B, Sokhna C, Boulanger D, Milet J, Ba EH, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet. 2006;367:659–67.
    1. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet. 2002;360:2031–2038.
    1. IRD web site, 2004; Unité de Service 09.
    1. Ndiaye F, Molez JF, Trape JF. Endémie palustre. In: Delaunay V, editor. La Situation Démographique et Épidémiologique dans la Zone de Niakhar au Sénégal. Dakar: ORSTOM; 1998. pp. 118–22.
    1. Sokhna CS, Molez JF, Ndiaye P, Sané B, Trape JF. Test in vivo de chimiosensibilité de Plasmodium falciparum à la chloroquine au Sénégal: évolution de la résistance et estimation de l'efficacité thérapeutique. Bull Soc Path Exot. 1997;90:83–89.
    1. Trape JF, Pison G, Preziosi MP. Impact of chloroquine resistance on malaria mortality. CR Acad Sci Paris Sci Vie/Life Sci. 1998;321:689–697.
    1. Rogier C, Ly AB, Tall A, Cisse B, Trape JF. Plasmodium falciparum clinical malaria in Dielmo, a holoendemic area in Senegal: no influence of acquired immunity on initial symptomatology and severity of malaria attacks. Am J Trop Med Hyg. 1999;60:410–20.
    1. Plowe, Djimdé A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565–8.
    1. Pearce CRJ, Drakeley D, Chandramohan F, Mosha C. Roper Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother. 2003;47:1347–54.
    1. Marks F, von Kalckreuth, Kobbe R, Adjei S, Adjei O, et al. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single dose sulfadoxine-pyrimethamine. J Infect Dis. 2005;192:1962–65.
    1. Mayor A, Sanz S, Espasa M. Point mutations in the dhfr, dhps, pfcrt and pfmdr1 P. falciparum genes within a clinical trial of intermittent Preventive Treatment (IPT) in infants. Acta Tropica. 2005;(95 supplement):S68.
    1. Kidane G, Morrow RH. Teaching mothers to provide home treatment of malaria in Tigray, Ethiopia: a randomised trial. Lancet. 2000;356:550–555.
    1. Menon A, Jood D, Rowan KM, Greenwood BM. Maternal administration of chloroquine: an unexplored aspect of malaria control. Journal of Tropical Medicine and Hygiene. 1988;91:49–54.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa